Plazomicin Sulfate Patent Expiration

Plazomicin Sulfate is Used for treating bacterial infections. It was first introduced by Cipla Usa Inc in its drug Zemdri on Jun 25, 2018.


Plazomicin Sulfate Patents

Given below is the list of patents protecting Plazomicin Sulfate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zemdri US8383596 Antibacterial aminoglycoside analogs Jun 02, 2031 Cipla Usa
Zemdri US8822424 Antibacterial aminoglycoside analogs Nov 21, 2028 Cipla Usa
Zemdri US9266919 Antibacterial aminoglycoside analogs Nov 21, 2028 Cipla Usa
Zemdri US9688711 Antibacterial aminoglycoside analogs Nov 21, 2028 Cipla Usa



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Plazomicin Sulfate's patents.

Given below is the list recent legal activities going on the following patents of Plazomicin Sulfate.

Activity Date Patent Number
Patent litigations
FDA Final Eligibility Letter 30 Jan, 2024 US8383596
FDA Final Eligibility Letter 30 Jan, 2024 US8822424
Payment of Maintenance Fee, 8th Yr, Small Entity 23 Aug, 2023 US9266919
transaction for FDA Determination of Regulatory Review Period 15 May, 2023 US8383596
transaction for FDA Determination of Regulatory Review Period 15 May, 2023 US8822424
transaction for FDA Determination of Regulatory Review Period 18 Apr, 2023 US8383596
transaction for FDA Determination of Regulatory Review Period 18 Apr, 2023 US8822424
Payment of Maintenance Fee, 8th Yr, Small Entity 02 Mar, 2022 US8822424
Payment of Maintenance Fee, 4th Yr, Small Entity 28 Dec, 2020 US9688711
Second letter to regulating agency to determine regulatory review period 24 Sep, 2020 US8383596


Plazomicin Sulfate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List